Researched and written by ChatGPT
Every so often, a study comes along that raises more questions than it answers. That is not a failure of science. In fact, that is often how science is supposed to work. A finding appears, researchers look at it from every possible angle, and if the signal is strong enough, someone eventually asks the obvious question: should we investigate this properly?
That is where we now find ourselves with ivermectin, mebendazole and cancer.
A 2026 study published in Anticancer Research followed cancer patients who were prescribed a combination of ivermectin and mebendazole, two inexpensive, long-established antiparasitic medications that are not currently approved as cancer treatments. The study began with 197 patients, and 122 completed the follow-up approximately six months later.
The results are what caught people's attention. Among those who completed the follow-up, 32.8 percent reported no current evidence of disease and another 15.6 percent reported tumor regression. Taken together, that means 48.4 percent reported either regression or no current evidence of disease. Another 36.1 percent reported stable disease.
Those numbers are interesting. They should be interesting to anyone who cares about finding better ways to treat cancer.
They are not, however, proof that ivermectin and mebendazole cured those patients. The study was observational rather than randomized, there was no control group, and outcomes were largely patient-reported. Many of the participants were also receiving other cancer treatments, including chemotherapy, radiation and surgery, while others were using supplements, dietary changes or additional complementary approaches.
That makes it impossible to look at these results and say with certainty which treatment produced which outcome.
But this is precisely where I believe the conversation too often goes wrong.
A study does not have to prove something beyond doubt before it becomes worthy of further investigation. In early research, the purpose is often to identify a signal strong enough to justify a better study. When nearly half of the responding patients in a prospective cohort report tumor regression or no evidence of disease while taking two inexpensive repurposed medications, I do not think the rational response is ridicule or dismissal.
I think the rational response is curiosity.
Why Aren't We Studying This More Aggressively?
Cancer remains one of the most frightening diagnoses a person can receive, and despite extraordinary advances in treatment, many patients are still faced with difficult choices, harsh side effects, uncertain outcomes and enormous expense.
That reality alone should make us hungry for more options.
Chemotherapy has undoubtedly saved lives. So have radiation, surgery, targeted therapy and immunotherapy. Recognizing that does not require us to pretend that our current treatments are perfect or that there is nothing left to discover.
Medicine should never become so attached to its existing tools that it loses interest in potentially useful ones simply because they came from somewhere unexpected.
Drug repurposing is particularly fascinating because it asks a very simple question: could medications that have already been used safely for other illnesses have applications we have not fully explored?
Ivermectin and mebendazole are not obscure experimental compounds that were invented last week. Both have been used in human medicine for decades. Researchers have also been studying possible anticancer effects of these drugs in laboratory and animal models for years, including effects on cancer-cell growth, signalling pathways and programmed cell death.
That does not mean laboratory findings automatically translate into successful cancer treatments in humans. Plenty of promising laboratory findings never do.
But again, that is what clinical research is for.
The Money Question Should Not Be Off Limits
There is also an economic aspect to drug research that deserves to be discussed without immediately being treated as a forbidden subject.
New patented cancer drugs can be extraordinarily valuable. Older generic medications generally cannot generate the same financial return. That does not prove that pharmaceutical companies are secretly suppressing successful cancer treatments, and I don't think we need to make that claim in order to raise legitimate concerns about research incentives.
Money influences what gets studied. That is simply reality.
Clinical trials are expensive, often enormously so, and companies understandably invest in treatments they have a financial incentive to develop. An inexpensive generic drug that cannot be protected by a lucrative patent may therefore have a much more difficult time attracting the funding required for large randomized trials.
That creates a troubling possibility.
What if some useful treatments remain under-investigated not because they failed, but because nobody stands to make enough money from proving that they work?
I don't know whether ivermectin or mebendazole will ultimately prove valuable in cancer treatment. Nobody does yet.
But I absolutely believe that question deserves an answer.
Give Us Good Research, Not Another Medical Tribe
There is an unfortunate tendency today for medical debates to become tribal. One side treats a drug as though it must be miraculous, while the other treats the very suggestion of studying it as dangerous or absurd.
Neither approach is particularly scientific.
If ivermectin and mebendazole do not meaningfully improve cancer outcomes, a well-designed clinical trial should be able to demonstrate that.
If they do improve outcomes, especially in particular cancers or in combination with other therapies, a well-designed clinical trial should reveal that too.
This does not require abandoning chemotherapy, radiation or any other existing treatment. It requires broadening our willingness to investigate possibilities.
The appropriate next step would be straightforward: independent multicentre trials involving clearly defined cancer types and stages, objective imaging and laboratory measurements, carefully documented concurrent treatments and proper control groups. Researchers should determine in advance what outcomes they are measuring and publish the results whether they are positive, negative or inconclusive.
That is the kind of science patients deserve.
Transparency Has to Work Both Ways
There is another part of this story that cannot be ignored.
Following publication of the 2026 ivermectin and mebendazole study, Anticancer Research issued an Expression of Concern regarding the paper.
That should be examined closely.
People who support further research into repurposed medicines should not hide uncomfortable information any more than pharmaceutical companies, regulators or medical institutions should.
If there are legitimate problems with this study, I want to know exactly what they are. If there are concerns about methodology, authorship, data collection, conflicts of interest or statistical interpretation, they should be laid out clearly and publicly.
Transparency cannot mean demanding evidence only from people we distrust.
It means demanding it from everyone.
If the study ultimately proves unreliable, then say so and explain why. If the concerns are resolved and the findings remain intact, that matters too.
What I do not want is a culture where questions simply disappear because they are inconvenient.
Cancer Patients Deserve Informed Choice
Imagine being told that you have cancer.
Your world changes in seconds.
Suddenly you are learning a new language of scans, pathology reports, stages, survival statistics, treatment protocols and side effects while simultaneously trying to process the fact that your own mortality has just become part of the conversation.
That is not the moment when patients need paternalism.
They need information.
Tell them what treatments have strong evidence behind them. Tell them what is experimental. Tell them what has promising laboratory evidence but little human evidence. Explain what is known, what is uncertain and what risks exist.
Then allow people to participate meaningfully in decisions about their own bodies.
I am increasingly uncomfortable with the idea that questioning a conventional treatment automatically makes someone anti-science. Science advances because people question what we already think we know.
Likewise, exploring an unconventional treatment should never require pretending that weak evidence is strong evidence.
We should be capable of holding both ideas at once.
This Study Does Not End the Conversation. It Begins One.
The viral headlines surrounding this research have exaggerated what happened. Nearly half of the patients did not prove that ivermectin cured their cancer. That conclusion cannot be drawn from this study.
But once the exaggeration is removed, something genuinely interesting remains.
A group of cancer patients taking ivermectin and mebendazole produced outcomes that the researchers themselves considered worthy of further investigation. Nearly half of the responding patients reported tumor regression or no current evidence of disease, despite the study's substantial limitations.
That should be enough to justify better research.
Maybe future trials will show that the drugs provide no meaningful benefit.
Maybe they will help only a narrow subgroup of patients.
Maybe they work best alongside conventional therapies rather than instead of them.
Or perhaps researchers will discover something nobody expected.
Whatever the answer is, I want to know.
Cancer patients deserve more than a handful of established treatment pathways and a warning not to look elsewhere. They deserve rigorous investigation of every credible possibility, especially treatments that are accessible, inexpensive and already familiar to medicine.
Study them properly.
Follow the patients.
Publish the data.
Disclose the conflicts.
Let independent researchers replicate the results.
And then allow people facing cancer to make decisions using the fullest, most transparent body of evidence we can possibly give them.
That isn't anti-medicine.
It is exactly what medicine should be.